HaemaLogiX initiates collaboration with Universidad de Navarra

1/1

On November 6, 2019, Haemalogix and Universidad de Navarra - Clínica Universidad de Navarra in Pamplona (Spain), signed an agreement with Dr. Ramón Lecumberri Villamediana to explore the mechanism of action of the anti-KMA and anti-LMA antibodies in a variety of in vitro and in vivo amyloidosis experiments.

AL Amyloidosis is characterised by deposition of light chain variable region complexes in tissues such as the heart which can lead to congestive heart failure. Currently the preferred treatment is autologous stem cell transplant (ASCT) which may be followed by bortezomib-based consolidation post-transplant in patients who do not achieve a very good partial response (VGPR). However, no more than 25% of newly diagnosed patients are eligible for ASCT due to advanced age, extent of cardiac failure and decreased renal function. Hence, there is a need for further therapies to help prevent amyloid deposits in tissues.

Our antibodies against kappa light chain and lambda light chain constant regions may sequester these free light chains before they can deposit in tissues.

redTextLogo